The UK ATTR Amyloidosis Patients’ Association (UKATPA) was founded in 2017 by a group of UK patients with transthyretin (TTR)-type systemic amyloidosis (ATTR), supported by the consultant physicians of the UK NHS National Amyloidosis Centre.

In this exciting environment of change and optimism, our members decided to found a UK patient group dedicated to the interests of people in the UK with ATTR amyloidosis and to ensuring their participation in patient care and in disease and therapeutic research.

Our key objectives will be enhancement of clinical and basic science research into ATTR amyloidosis, facilitation of patient participation in clinical trials of new drugs for ATTR amyloidosis and expediting drug approval processes.  When new drugs for ATTR amyloidosis receive licensing approval we will aim to ensure clinically appropriate access for all UK ATTR amyloidosis patients.